Key Highlights
- Revenue was USD 18.88 million against an estimate of USD 20.78 million.
- Loss per share was USD 0.57 against an estimate of a USD 0.42 loss.
- Research and development expense was USD 36.56 million, against USD 24.26 million.
- Cash and marketable securities were USD 565.2 million at September 30.
Septerna (NASDAQ:SEPN) reported third quarter 2026 Revenue of USD 18.88 million, against an estimate of USD 20.78 million and USD 21.50 million in the third quarter of 2025. The loss per share was USD 0.57, compared with an estimate of a USD 0.42 loss.
The loss from operations was USD 27.23 million, compared with income from operations of USD 2.61 million in the prior-year quarter, which included a USD 12.5 million gain on sale of a non-financial asset. Total operating expenses were USD 46.11 million, against USD 18.88 million.
Operating Expenses
Research and development expenses were USD 36.56 million, compared with USD 24.26 million. General and administrative expenses were USD 9.6 million, compared with USD 7.1 million, primarily due to USD 2.7 million of higher employee-related costs from increased headcount.
Stock-based compensation within Research and Development expense was USD 2.57 million, compared with USD 1.49 million, and within general and administrative expense was USD 3.35 million, compared with USD 1.04 million. Interest income was USD 5.27 million, compared with USD 5.57 million. For the nine months, revenue was USD 72.15 million, against USD 21.83 million, and total operating expenses were USD 129.52 million, against USD 74.11 million.
Nine-Month Results
The nine-month loss from operations was USD 57.37 million, compared with USD 52.27 million. Research and development expenses for the nine months were USD 101.22 million, against USD 65.72 million, and general and administrative expenses were USD 28.29 million, against USD 20.88 million.
Interest income for the nine months was USD 15.10 million, against USD 14.19 million. Accounts Receivable were USD 18.88 million at September 30, 2026, compared with USD 10.36 million at the prior Balance Sheet date. Cash and cash equivalents were USD 167.12 million, compared with USD 120.72 million, and marketable securities were USD 311.48 million, compared with USD 270.37 million.
SEP-479 Program and Liquidity
On April 13, 2026, the company announced the dosing of the first participants in a Phase 1 clinical trial of SEP-479, an oral small molecule PTH1R agonist being developed for hypoparathyroidism. The randomized, placebo-controlled trial includes single-ascending and multiple-ascending dose cohorts to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adults, and is designed to enroll up to 150 participants.
The company said the observed terminal half-life of SEP-479 from ongoing Phase 1 data is approximately three to four days, which it anticipates supports once-daily dosing. The company believes its cash, cash equivalents and marketable securities of USD 565.2 million as of September 30, 2026 are sufficient to fund operations and Capital Expenditure requirements at least into mid-2029.
Septerna Q3 2026 Earnings: Key Takeaways
Septerna reported third quarter 2026 revenue of USD 18.88 million and a loss per share of USD 0.57. Research and development expense was USD 36.56 million, and cash, cash equivalents and marketable securities were USD 565.2 million.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...